KRAS mutations were detected in plasma from CRC patients, however it was also reported that 0.45–20% of healthy individuals may carry genomic alterations in cfDNA, with particular regard to TP53 and KRAS variants [72]. Here, TP53 is linked to colorectal carcinoma.